adms-20210223

0001328143-21-000020.txt : 20210223 0001328143-21-000020.hdr.sgml : 20210223 20210223160510 ACCESSION NUMBER: 0001328143-21-000020 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210223 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210223 DATE AS OF CHANGE: 20210223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36399 FILM NUMBER: 21665364 BUSINESS ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-3554 MAIL ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 8-K 1 adms-20210223.htm 8-K adms-20210223

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 23, 2021

ADAMAS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36399

42-1560076

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer Identification No.)

1900 Powell Street, Suite 1000

Emeryville, CA 94608

(Address of principal executive office)

Registrant’s telephone number, including area code (510) 450-3500

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ADMS

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 23, 2021, Adamas Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.						Description
99.1						99.1 Press Release dated February 23, 2021.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		Adamas Pharmaceuticals, Inc.

Dated:	February 23, 2021	By:	/s/ Christopher B. Prentiss
			Christopher B. Prentiss
			Chief Financial Officer

EX-99.1 2 adms2020q4991.htm EX-99.1 Document

Exhibit 99.1

Adamas Reports Fourth Quarter and Full Year 2020 Financial Results

Fourth Quarter 2020 total revenues of $21.0 million, a 29% increase over fourth quarter 2019

Full Year 2020 total revenues of $74.5 million, a 36% increase over 2019

Second indication received February 2021 for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinson’s disease patients experiencing OFF episodes

EMERYVILLE, Calif., February 23, 2021 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020, and recent corporate highlights.

“We are excited with the opportunities ahead of us, including the continued growth of GOCOVRI which is now the first and only medication approved to treat both OFF and dyskinesia motor complications in Parkinson’s disease,” said Neil F. McFarlane, Chief Executive Officer. “Bolstered by the launch of a second indication, GOCOVRI is now approved to treat approximately 400,000 to 500,000 Parkinson’s patients. The significant progress made across the business in 2020 fueled positive momentum into 2021, and we are leveraging this as we continue to successfully execute our long-term growth strategy.”

Recent portfolio highlights

•Total revenues were $21.0 million in the fourth quarter of 2020, an increase of 29% as compared to $16.3 million in the fourth quarter of 2019.

•GOCOVRI® (amantadine) extended release capsules product sales were $19.8 million in the fourth quarter of 2020, an increase of 21% as compared to $16.3 million in the fourth quarter of 2019.

•Total paid prescriptions (TRx) of GOCOVRI were approximately 8,165 in the fourth quarter of 2020, a 14% increase over approximately 7,160 TRx in the fourth quarter of 2019.

•Strong patient persistence of 45%-50% at 12 months continued in the fourth quarter of 2020.

•New paid prescriptions (NRx) of GOCOVRI were approximately 510 in the fourth quarter of 2020, a 19% increase over NRx of approximately 430 in the third quarter of 2020.

•In February 2021, the U.S. Food and Drug Administration approved a second indication for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinson’s disease patients experiencing OFF episodes.

Corporate highlights

•In January 2021, closed the settlement of patent litigation with Osmotica Pharmaceuticals plc. and completed the acquisition of the global rights to OSMOLEX ER® (amantadine) extended release tablets, expanding Adamas’ neurology portfolio.

•Amended certain key terms of the Royalty-Backed Loan agreement with HealthCare Royalty Partners, which became effective with the closing of the acquisition of OSMOLEX ER.

•In February 2021, announced a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving patent litigation between the two parties relating to Zydus’ ANDA referencing GOCOVRI. Under the agreement Adamas granted Zydus a non-exclusive license to begin selling a generic version of GOCOVRI as of March 4, 2030, or earlier in certain circumstances.

Financial results

Revenue

Total revenue was $21.0 million for the fourth quarter of 2020, consisting of GOCOVRI product sales of $19.8 million and royalty revenue earned on net sales of NAMZARIC® (memantine hydrochloride extended release and donepezil hydrochloride) capsules of $1.2 million. GOCOVRI product sales were up 21% compared to $16.3 million in the same period in 2019.

Total revenue was $74.5 million for full year 2020, consisting of GOCOVRI product sales of $71.2 million and royalty revenue earned on net sales of NAMZARIC of $3.3 million. GOCOVRI product sales were up 30% compared to $54.6 million in 2019.

Research and Development (R&D) expenses

R&D expenses for the fourth quarter of 2020 were $2.4 million, compared to $5.2 million for the same period in the prior year. R&D expenses in the fourth quarter of 2020 substantially relate to the ongoing open-label study which concluded at the end of 2020. The decrease in R&D expenses from the prior year quarter was primarily due to the completion of the Phase 3 INROADS trial for the treatment of multiple sclerosis patients with walking impairment at the end of 2019.

R&D expenses for full year 2020 were $9.7 million, compared to $30.0 million in 2019. The decrease in R&D expenses from 2019 was primarily due to the completion of the Phase 3 INROADS trial for the treatment of multiple sclerosis patients with walking impairment at the end of 2019.

Selling, General and Administrative (SG&A) expenses

SG&A expenses for the fourth quarter of 2020 were $33.0 million, compared to $30.3 million for the same period in the prior year. SG&A expenses in the fourth quarter of 2020 were primarily attributable to sales force costs and external spend dedicated to GOCOVRI commercialization and the related administrative support. The fourth quarter of 2020 includes approximately $5.0 million related to one-time charges associated with the settlement of patent litigation and acquisition of the global rights to OSMOLEX ER.

SG&A expenses for 2020 were $106.8 million, compared to $114.4 million for the same period in the prior year. The decrease from 2019 was primarily attributable to certain one-time charges related to personnel transitions incurred in the third quarter of 2019.

Net loss

Net loss was $18.3 million, or $0.64 per share, basic and diluted, for the fourth quarter of 2020, compared to a net loss of $23.1 million, or $0.83 per share, basic and diluted, for the fourth quarter of 2019. Net loss for the fourth quarters of 2020 and 2019 included $1.6 million and $2.1 million, respectively, in non-cash stock-based compensation expense.

Net loss was $57.4 million, or $2.03 per share, basic and diluted, for full year 2020, compared to a net loss of $105.2 million, or $3.80 per share, basic and diluted, for 2019. Net loss for 2020 and 2019 included $6.4 million and $12.9 million, respectively, in non-cash stock-based compensation expense.

Cash and investments

As of December 31, 2020, Adamas had $83.4 million of cash, cash equivalents and available-for-sale securities. Subsequent to December 31, 2020, and through February 16, 2021, Adamas raised net proceeds of approximately $7.2 million under an at-the-market offering.

Full year 2021 expense guidance

For full year 2021, Adamas estimates R&D, SG&A and stock-based compensation expenses as set forth below:


						Full Year 2021
R&D expenses						$5 million -- $10 million1
SG&A expenses						$110 million -- $120 million2
Total operating expenses						$115 million -- $130 million3

1Includes stock-based compensation expense of $1 million.

2Includes stock-based compensation expense of $8 million.

3Includes stock-based compensation expense of $9 million.

Investor conference call and webcast

Adamas will host a conference call and webcast today, February 23, 2021, at 4:30 p.m. ET (1:30 p.m. PT). The conference call can be accessed by dialing 1-877-407-9716 for participants in the U.S. or Canada and 1-201-493-6779 for international callers. All callers must provide the following Conference ID: 13716505. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay for approximately 30 days.

About GOCOVRI

GOCOVRI® (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes.

Taken once daily at bedtime, GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day. Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls and orthostatic hypotension.

For more information about GOCOVRI, please visit www.GOCOVRI.com.

About OSMOLEX ER

OSMOLEX ER® (amantadine) extended release tablets is FDA-approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. OSMOLEX ER is contraindicated in patients with end-stage renal disease (i.e., creatinine clearance below 15 mL/min/1.73 m2). The most common adverse reactions reported in ≥5% of patients at the recommended dosage of immediate-release amantadine were nausea, dizziness/lightheadedness, and insomnia.

For more information about OSMOLEX ER, including the full Prescribing Information, please visit www.OSMOLEX.com.

NAMZARIC

For more information, please visit www.NAMZARIC.com.

About Adamas

At Adamas our vision is clear - to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Forward-looking statements

Statements contained in this press release regarding matters that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding Adamas’ expectations of its full year 2021 expenses. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas’ research, clinical, development and commercial activities relating to GOCOVRI and ADS-5102, and the regulatory and competitive environment and Adamas’ business in general, see Adamas’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 23, 2021, particularly under the caption “Risk Factors.” In addition, the impact that the current COVID-19 pandemic is having and will have on demand for GOCOVRI, and the unknown duration and severity of the COVID-19 pandemic, add additional risk and uncertainty to these forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

# # #

Contact:


Media:
Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.com

Investors:
Peter Vozzo Managing Director, Westwicke/ICR 443-213-0505 peter.vozzo@westwicke.com

— Financial Tables Attached —

Adamas Pharmaceuticals, Inc.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except per share data)


	Three Months Ended December 31,				Twelve Months Ended December 31,
	2020		2019		2020		2019
Revenues:
Product sales	$	19,761	$	16,348	$	71,166	$	54,637
Royalty revenue	1,249		—		3,295		—
Total revenues	21,010		16,348		74,461		54,637
Costs and operating expenses:
Cost of product sales	597		442		2,038		2,469
Research and development	2,398		5,180		9,746		30,034
Selling, general and administrative, net	32,992		30,285		106,841		114,369
Total costs and operating expenses	35,987		35,907		118,625		146,872
Loss from operations	(14,977)		(19,559)		(44,164)		(92,235)
Interest and other income, net	94		124		748		2,093
Interest expense	(3,390)		(3,640)		(13,987)		(15,044)


Net loss	$	(18,273)	$	(23,075)	$	(57,403)	$	(105,186)
Net loss per share, basic and diluted	$	(0.64)	$	(0.83)	$	(2.03)	$	(3.80)
Weighted average shares used in computing net loss per share, basic and diluted	28,617		27,890		28,305		27,677

Adamas Pharmaceuticals, Inc.

Unaudited Consolidated Balance Sheet Data

(in thousands)


	December 31, 2020		December 31, 2019
Cash, cash equivalents, and available-for-sale securities	$	83,365	$	132,607
Total assets	120,029		162,158
Total current liabilities	34,867		26,948
Long-term debt	126,307		125,674
Total liabilities	170,005		163,051
Total stockholders’ deficit	(49,976)		(893)

EX-101.SCH 3 adms-20210223.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 adms-20210223_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 adms-20210223_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 adms-20210223_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two Document Information [Line Items] Document Information [Line Items] City Area Code City Area Code Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 adms-20210223_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 adms-20210223_htm.xml IDEA: XBRL DOCUMENT 0001328143 2021-02-23 2021-02-23 0001328143 false 8-K 2021-02-23 ADAMAS PHARMACEUTICALS, INC. DE 001-36399 42-1560076 1900 Powell Street Suite 1000 Emeryville CA 94608 510 450-3500 false false false false Common Stock, par value $0.001 per share ADMS NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 23, 2021
Document Information [Line Items]
Document Type	8-K
Document Period End Date	Feb. 23, 2021
Entity Incorporation, State or Country Code	DE
Entity File Number	001-36399
Entity Tax Identification Number	42-1560076
Entity Address, Address Line One	1900 Powell Street
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	450-3500
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	ADMS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001328143
Amendment Flag	false
Entity Registrant Name	ADAMAS PHARMACEUTICALS, INC.

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://adamaspharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports adms-20210223.htm adms-20210223.xsd adms-20210223_cal.xml adms-20210223_def.xml adms-20210223_lab.xml adms-20210223_pre.xml adms2020q4991.htm http://xbrl.sec.gov/dei/2019-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adms-20210223.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "adms-20210223_cal.xml" ] }, "definitionLink": { "local": [ "adms-20210223_def.xml" ] }, "inline": { "local": [ "adms-20210223.htm" ] }, "labelLink": { "local": [ "adms-20210223_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "adms-20210223_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "adms-20210223.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adms", "nsuri": "http://adamaspharma.com/20210223", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adms-20210223.htm", "contextRef": "i6b23edca1f4e4d2e93405e00e838d981_D20210223-20210223", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://adamaspharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adms-20210223.htm", "contextRef": "i6b23edca1f4e4d2e93405e00e838d981_D20210223-20210223", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001328143-21-000020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001328143-21-000020-xbrl.zip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end